Yes. Apixaban is the generic chemical name for the anticoagulant most know by its brand name, Eliquis. Both labels describe the same active compound, delivered in the same 2.5 mg and 5 mg tablets, working through the same Factor Xa mechanism in the bloodstream. The names differ because one is the scientific identifier and the other is the trade name under which Bristol-Myers Squibb first sold it.
This guide covers what actually shifts when a prescription says apixaban instead of Eliquis, from FDA approval pathways to the Factor Xa action in your bloodstream.
Apixaban and Eliquis Share the Same Active Ingredient
Picture standing at the pharmacy with a prescription that reads Eliquis one visit and apixaban the next. Same pill strength, different label. That moment of confusion is common, and it stems from a naming convention that applies to nearly every prescription drug in circulation.
Apixaban is the generic chemical name, the official scientific label for the molecule itself. Eliquis is the brand name assigned by Bristol-Myers Squibb, the company that developed the drug and moved it through clinical trials. Pfizer joined as a co-marketer after FDA approval, so you may see both companies referenced in connection with the medication. Whether your bottle says apixaban or Eliquis, the active ingredient arriving in your bloodstream is identical.
What “Active Ingredient” Actually Means
The active ingredient is the compound that produces the therapeutic effect, in this case, thinning the blood to reduce clot formation. Inactive ingredients, sometimes called excipients, are the fillers, dyes, and binders that hold a tablet together or help it dissolve. Regulators require generic versions to match the brand in active ingredient, strength, and dosage form, while allowing some flexibility in those inactive components.
That regulatory parity also explains why the following approval and oversight process treats generics as close substitutes rather than separate products.
| Feature | Brand (Eliquis) | Generic (Apixaban) |
|---|---|---|
| Active ingredient | Apixaban | Apixaban |
| Tablet strengths | 2.5 mg and 5 mg | 2.5 mg and 5 mg |
| Original manufacturer | Bristol-Myers Squibb / Pfizer | Various approved manufacturers |
| FDA-approved | December 2012 | Late 2019 onward |
Tip: When filling a refill, check the label for the active ingredient line. It should read “apixaban” regardless of whether the brand or generic was dispensed.
How Brand-Name and Generic Drugs Are Approved and Regulated
Eliquis received FDA approval in December 2012 for stroke prevention in people with nonvalvular atrial fibrillation. Approval followed large clinical trials showing the drug reduced stroke risk compared with older anticoagulants like warfarin, with a more predictable effect that didn’t require routine blood monitoring. Bristol-Myers Squibb held the original patent, which gave the company exclusive rights to sell the drug for a defined period.
Once those patent protections expired, other manufacturers could apply to produce their own versions. Generic apixaban entered the U.S. market in late 2019, and additional manufacturers have since joined, expanding the supply. FDA bioequivalence standards require generics to deliver the same amount of active ingredient into the bloodstream over the same timeframe as the brand, within a narrow statistical range.
The Bioequivalence Standard in Plain Language
Bioequivalence sounds technical, but the idea is straightforward. Take a 5 mg Eliquis tablet and a 5 mg generic apixaban tablet on separate occasions under the same conditions, and the concentration of drug in your blood should rise and fall along nearly identical curves. The FDA sets the acceptable range, typically within 80% to 125% of the brand’s absorption, and most approved generics sit even closer to the original. For most patients, that difference is too small to matter clinically.
What Actually Changes Between Brand and Generic Versions
Three things tend to differ, and understanding them removes most of the mystery at the pharmacy counter.
Visible Appearance and Packaging
Generic manufacturers cannot copy the brand’s exact pill color, shape, or imprint, because those details belong to the original company’s design. Your generic apixaban tablet may be a different shade of pink, a slightly different oval, or stamped with a different code. The packaging will reflect the new manufacturer’s branding, and the label will list a different drug company. None of those visual differences affect how the medication works.
Inactive Ingredients
Fillers, binders, and dyes can vary between formulations. Most people never notice the difference, but a small subset may have a sensitivity to a specific dye or component that another manufacturer avoids. If you’ve ever reacted to an inactive ingredient in another medication, flag that history to your pharmacist before accepting a new generic.
Cost and Insurance Coverage
Brand-name Eliquis carried a list price well above $500 per month for many years, which is part of why the question of generic availability matters so much. Once generic apixaban launched, prices dropped sharply. Insurance formularies often place generics on lower copay tiers, so a refill may shift from a high-tier brand copay to a much smaller generic copay overnight.
| Factor | Brand (Eliquis) | Generic (Apixaban) |
|---|---|---|
| Tablet color and imprint | Manufacturer-specific design | Varies by approved generic maker |
| Inactive fillers and dyes | Original formulation | May differ slightly |
| Out-of-pocket cost | Typically higher copay tier | Typically lower copay tier |
| Labeled manufacturer | Bristol-Myers Squibb / Pfizer | Various FDA-approved makers |
Safety, Efficacy, and the Factor Xa Mechanism
Whether your pill came from the original brand or a generic maker, the compound in your bloodstream acts on the same target. Apixaban is classified as a direct Factor Xa inhibitor, a type of anticoagulant often called a blood thinner, though it doesn’t actually thin the blood. Factor Xa is an enzyme that plays a central role in the clotting cascade, the series of steps your body uses to form a clot after injury. By selectively blocking Factor Xa, apixaban slows the rate at which clots form, lowering the risk of stroke and other clot-related events.
Approved Uses and Standard Dosing
The FDA has approved apixaban for several indications. The most common is stroke prevention in people with nonvalvular atrial fibrillation, a heart rhythm condition that raises stroke risk. The drug is also approved for treating deep vein thrombosis (DVT) and pulmonary embolism (PE), and for reducing the risk of these clots returning after initial treatment. Following your prescribing clinician’s instructions for your specific indication matters, because dosing schedules can differ by condition.
For most adults with nonvalvular atrial fibrillation, the standard regimen is 5 mg taken twice daily. A 2.5 mg twice-daily option exists for specific patient groups, often those with certain kidney function thresholds or who meet two of three age, weight, or creatinine criteria. DVT and PE treatment may begin with a higher-intensity period before stepping down, depending on what your clinician decides.
Because dosing can shift with age, weight, or kidney function, clinicians sometimes specify apixaban directly to control how the prescription is filled.
Expert Tip: Anticoagulants like apixaban carry a narrow safety window. Bleeding risk rises if the dose is too high for your kidney function, age, or weight, while clot risk returns if the dose is too low. Never adjust your schedule without your prescriber’s guidance.
Reasons Doctors Write Apixaban Instead of Eliquis on a Prescription
Prescribers often default to the generic name for practical reasons that have nothing to do with your health outcome and everything to do with how the prescription travels through the system. When a clinician writes “apixaban,” the pharmacy can dispense either the brand or any FDA-approved generic, giving the dispensing pharmacist flexibility to fill based on current supply and your insurance.
Electronic Prescribing and Insurance Workflows
Most electronic prescribing platforms encourage generic names as the default entry, which speeds up transmission and reduces typo risk. Insurance company formularies often cover the generic at a lower copay tier, and many plans require a trial of the generic before approving the brand. State laws in a number of areas also allow or require pharmacists to substitute an equivalent generic unless the prescriber writes “dispense as written” on the script.
- Default generic selection: Many EHRs default to the generic name to streamline refill workflows.
- Insurance mandates: Formularies frequently require generic trials before covering the brand version.
- State substitution laws: Several states permit automatic substitution unless “DAW” is specified.
- Cost transparency: Generic labeling makes the lower price visible at the point of sale.
- Supply flexibility: A generic prescription lets the pharmacy choose among approved makers.
When Switching Between Versions Deserves a Pharmacist Conversation
Switching from brand to generic, or between two different generic makers, is generally uneventful for most patients. Still, a short conversation with your pharmacist or prescriber is worth having in specific situations where the consistency of supply matters more than usual.
Sudden Appearance Changes and Refill Consistency
Pharmacies can switch suppliers from month to month based on which wholesaler offers the best price. Your pill may look slightly different with each refill, even though the active ingredient is unchanged. If a new shape, color, or imprint catches you off guard, ask the pharmacist to confirm it’s still apixaban from an approved manufacturer. For chronic regimens where you take the same pill every day, that quick check provides peace of mind.
Bleeding, Bruising, and Missed Doses
Anticoagulants sit at the edge of a safety window. Too much raises bleeding risk; too little lets clots form. Unusual bruising, prolonged bleeding from a small cut, blood in urine or stool, severe headaches, or dizziness that doesn’t resolve should be flagged to your prescribing clinician right away. Equally important is taking every dose on schedule. Apixaban’s short half-life means missing a dose can leave you under-protected within hours.
Those practical risks underscore why the next section distills the whole comparison into a single bottom-line judgment for patients weighing the two names.
Warning: Never stop, restart, or change the dose of your anticoagulant without first speaking with the prescriber who wrote the prescription. Sudden changes can raise the risk of stroke or serious bleeding events.
Bottom Line: One Medication, Two Names, Same Outcome
One medication, two labels, identical therapeutic effect. Apixaban and Eliquis refer to the same active compound, and FDA bioequivalence standards exist so that generic versions deliver essentially the same clinical result as the brand. Cost differences come from market dynamics, not quality, when the generic comes from an FDA-approved source.
- Confirm the active ingredient: Your pill’s label should list apixaban regardless of brand or generic status.
- Ask about manufacturer changes: A quick pharmacy conversation clears up any visual surprise between refills.
- Keep follow-up appointments: Kidney function and bleeding risk are monitored on a regular schedule.
- Report unusual symptoms early: Bruising, bleeding, or dizziness deserves a same-day call to your clinician.
- Never self-adjust dosing: Anticoagulant schedules are tailored to your labs, age, and weight.
The strongest next step is to confirm with your pharmacist which version is currently in the bottle, keep all follow-up appointments on schedule, and reach out to your prescriber before making any change to how you take it.
Final Takeaways
The clearest takeaway is that apixaban and Eliquis are two names for one medication, regulated to perform the same way in your body. If cost, appearance, or label naming has raised questions, the answer sits in the active ingredient line and the FDA approval mark, not in the marketing on the box. Keep your pharmacist in the loop, attend your monitoring visits, and treat any unusual bleeding as a prompt to call your clinician.
FAQ
Is apixaban the same as Eliquis?
Yes. Apixaban is the generic chemical name for the drug sold under the brand name Eliquis. Both contain the same active ingredient in the same tablet strengths, and FDA bioequivalence standards require generics to work the same way as the brand in your body.
What is the generic name for Eliquis?
Apixaban is the generic designation assigned to Eliquis after its manufacturer lost market exclusivity. Generic versions have been available in the U.S. since late 2019, after the original patent protections expired and additional manufacturers received FDA approval to produce their own versions.
Is apixaban cheaper than Eliquis?
A 30-day supply of generic apixaban often costs $40 or less, compared with roughly $550 for brand-name Eliquis at many U.S. pharmacies. Out-of-pocket prices can vary by pharmacy and manufacturer, so checking with your pharmacist before a refill is a smart move.
Are apixaban and Eliquis interchangeable?
For most patients, yes. The FDA considers them therapeutically equivalent, and pharmacists can substitute one for the other unless your prescriber writes “dispense as written.” Always confirm with your pharmacist if the pill’s appearance changes between refills.
Why did my pharmacist give me apixaban instead of Eliquis?
Many state laws allow or require generic substitution, and your insurance may cover the generic at a lower copay. Electronic prescribing systems also default to the generic name. The active ingredient in your bottle is still apixaban, just labeled with its scientific name.
Who manufactures apixaban and Eliquis?
Eliquis was developed by Bristol-Myers Squibb and is co-marketed with Pfizer. Generic apixaban is produced by several FDA-approved manufacturers that entered the market after the original patent expired in late 2019.
